EVEREST MED (01952) soared as much as 89% in early trading on the Hong Kong Stock Exchange, with shares last up 54.62% at HK$36.80, on turnover of HK$759 million.

The innovative drugmaker EVEREST MED (01952.HK) released its interim results for the six months ended June 30, 2026, along with the latest business updates. The report showed the company achieved total revenue of RMB 1.148 billion in the first half of the year, a 157% year-on-year increase, with a gross margin of 73.7%. Through continued optimization of resource allocation and improvements in operational efficiency, the company's profitability improved significantly, with Non-IFRS net profit reaching RMB 97.23 million and regular operating profit of RMB 48.12 million, achieving a turnaround to profitability year-on-year. As of the end of the first half, the cash balance stood at RMB 1.859 billion.

After the reporting period, in July 2026, the company received a RMB 770 million upfront payment under the global licensing and collaboration agreement for EVER001, further bolstering its cash position. The continued strengthening of the company's overall financial position provides solid support for future research and development investments and business expansion.

On August 19, Moderna and Merck announced initial positive results from the first Phase III trial of their mRNA personalized cancer vaccine, intismeran autogene. The vaccine, combined with Keytruda, met key endpoints of recurrence-free survival and reduced risk of distant metastasis in more than 1,100 high-risk melanoma patients who had undergone complete surgical resection. Catalyzed by this news, Moderna's stock surged nearly 177% overnight. The success of this melanoma Phase III trial is seen by the market as a key milestone in validating the feasibility of the mRNA personalized cancer vaccine technology pathway, potentially triggering a value reassessment of the entire sector.